urology oncology
D'Amico Risk Classification for Prostate Cancer
Stratifies prostate cancer risk into low, intermediate, and high categories based on PSA, Gleason score, and clinical T stage. Widely used to guide initial treatment decisions.
References
- D'Amico AV et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–974.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Gleason Score / Grade Group for Prostate Cancer · Prostate Cancer
- Prostate Cancer Risk Stratification (NICE / EAU) · Prostate Cancer
- UCSF-CAPRA Score for Prostate Cancer · Prostate Cancer
- PSA Doubling Time (PSADT) Calculator · Prostate Cancer
- PSA Velocity and PSA Density · Prostate Cancer
- D'Amico Risk Stratification for Localised Prostate Cancer · Prostate Cancer
Drugs
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Dalteparin · Low Molecular Weight Heparin — VTE Treatment / Cancer-Associated Thrombosis
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.